Open

Newly Diagnosed Secondary AML Research Study

This is a research study to find out if giving a combination of drugs (tagraxofusp and azacitidine) will treat your leukemia and keep it inactive for a period of time.

Age & Gender

18 years ~ 99 years
Male, Female, Gender Inclusive

Visit Availability

Standard business hours (M-F, 8-5)

Location

United States (Nationwide)

What will be asked of you

At each study visit, you will meet with a team member who will ask you questions about your health, physical examination, vital signs, blood draws, and bone marrow biopsy at certain visits.

Incentives

Study medication

In-person visits:
8+

Total length of participation:
24 months

Looking for Specific Volunteers

Able to participate:

You have a new diagnosis of Acute Myeloid Leukemia
You are 18 or older
You have good kidney and liver function

Not eligible if:

You have had previous chemotherapy treatment
You have other previous cancer diagnosis
You have significant heart or lung disease
You are pregnant

Contact the Team

Visit Location

Contact & Visit Location

Primary Contact

Lineberger Clinical Research
cancerclinicaltrials@med.unc.edu
(919) 966-4432

Primary Visit Location

Lineberger Comprehensive Cancer Center
NC Cancer Hospital (Basnight)
UNC Hospitals / UNC Medical Center
101 Manning Dr, Chapel Hill, NC 27514, USA

Additional Study Information

Principal Investigator

Joshua Zeidner
LCCC - Clinical Trials

Study Type

Clinical or Medical
Interventional

Study Topics

Cancer (Leukemia)

IRB Number

22-1074

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Helpful Links

Questions?

This email address is being protected from spambots. You need JavaScript enabled to view it.